Just from poking around - FierceBiotech, etc - my impression is that CLVS rocketed on the news about the ovarian and breast cancer patients (treated with a different drug), rather than about their NSCLC data.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.